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TO THE EDITOR
Management of Patients
With Acute Myocardial
Infarction and
Cardiogenic Shock
We were interested to read the paper by Lemor et al.
(1), which compared 198 patients from the NCSI
(National Cardiogenic Shock Initiative) trial who
were treated with either multivessel percutaneous
coronary intervention (MV-PCI) or culprit-vessel PCI
(CV-PCI) for acute myocardial infarction with
cardiogenic shock (AMICS). Patients who underwent
MV-PCI had a worse lactate (5.6 vs. 5.0 mg/dl) and
cardiac output impairment (3.8 vs. 4.0 l/min) on
presentation. Despite this, the 24-h post-
intervention outcomes were similar.
Sabell et al. (2) analyzed a subset of 158 patients
from the CardShock study (CardShock Study and
Registry) to explore the association between
angiographic results and 90-day mortality. Fifty-eight
percent of patients survived post-operatively, and
81% of survivors had TIMI (Thrombolysis In
Myocardial Infarction) flow grade 3 post-operatively
compared with 60% of those who died. Moreover, the
timing of cardiogenic shock (CS) played no role in
patients with successful revascularization, with 32%
of these patients developing CS pre-operatively and
34% developing CS post-operatively. Forty percent of
survivors had single-vessel coronary artery disease,
34% had 2-vessel disease, and 26% had 3-vessel
disease. Lemor et al. (1) did not explicitly
subcategorize multivessel disease, and this an
interesting perspective they may want to consider in
the future.
Helgestad et al. (3) studied the use of mechanical
circulatory support in patients with AMICS who were
undergoing PCI between 2010 and 2017 from the
Danish National Patient Registry. Forty patients were
supported with early intra-aortic balloon pump, and
40 were supported with the Impella CP device
(Abiomed, Danvers, Massachusetts), both were
compared with matched control groups. Use of the
early Impella CP resulted in a significantly lower 30-
day mortality compared with the matched control
group (40% vs. 77.5%; p < 0.001). Lemor et al. (1) did
not specify which particular Impella device was
included in their study.
We agree with the investigators that in patients
with multivessel coronary artery disease who present
with AMICS, MV-PCI of nonculprit lesions with early
mechanical circulatory support is a safe and effective
treatment protocol.
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REPLY: Cardiogenic Shock Management
Will Never Be All or None
We read with interest the letters from Drs. Rao and
Thiele and Khan and colleagues concerning our
paper (1). Though randomized control trials (RCTs)
are the gold standard of evidence-based medicine,
simply dismissing the results of a well-conducted,
prospective, single-arm study is unfair. In the past 2
decades, only w2,500 patients have been enrolled
into RCTs worldwide, representing <0.05% of cases
(2). A single RCT, therefore, can and should be
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appropriately scrutinized. Patients enrolled into the
CULPRIT-SHOCK (Culprit Lesion Only PCI versus
Multi- vessel PCI in Cardiogenic Shock) trial were
infrequently treated with mechanical circulatory
support (MCS), unlike the patients in our study.
Though MCS has yet to be sufficiently studied in an
appropriately powered RCT, studies have
demonstrated superior hemodynamic support and
coronary perfusion with their use. Similarly, the use
of an impractical revascularization strategy with the
inclusion of chronic total occlusion percutaneous
coronary intervention (PCI), may subject patients to
the hemodynamic risks of PCI without the
hemodynamic benefit of PCI, given the chronic
nature of the occlusion. Hence, further study is
warranted.
The National Cardiogenic Shock Initiative is the
largest working group evaluating outcomes in acute
myocardial infarction complicated by cardiogenic
shock. It includes >60 sites and has enrolled >350
patients. Patients are enrolled using a shock defini-
tion and inclusion/exclusion criteria similar to pre-
viously conducted RCTs. The protocol was written in
2016, at which time both U.S. and European guide-
lines supported multivessel PCI (MV-PCI). In regard
to MV-PCI, our protocol states, “We recommend
against non-culprit PCI unless flow is impaired in the
involved artery (i.e., less than TIMI [Thrombolysis In
Myocardial Infarction] flow grade 3 and excluding
chronic total occlusions); however, the ultimate de-
cision of multi-vessel PCI lies with the primary
operator.” Our protocol recommendation was made
before the results of the culprit shock trial with the
understanding that complex hemodynamic changes
occur during PCI. Balloon inflations cause transient
cessation of blood flow and embolization, which can
impair left ventricular function (3). However,
selective MV-PCI may be appropriate in many
settings as is mentioned by the 2017 European
Society of Cardiology Task Force such as in the
presence of multiple culprit arteries and in flow-
limiting or severely obstructive lesions that
jeopardize a large myocardial territory (4). Thus,
the results of our study are important, given these
scenarios frequently occur and may be better
tolerated with the use of MCS.
We do regret that we did not report the odds ratio
in the paper, which is included herein. The adjusted
odds ratio for hospital survival was 1.70 (95% confi-
dence interval: 0.79 to 3.63). Covariates included in
the multivariate model included age, sex, and base-
line comorbidities.
We read with interest the letter from Dr. Khan and
colleagues. The Central Illustration subcategorizes
patients on the basis of diseased vessels; 34% of pa-
tients (102 of 300) had single-vessel disease, 33% (100
of 300) had 2-vessel disease, and 33% (98 of 300) had
3-vessel disease (1). Similarly, Table 2 lists the Impella
used (Abiomed, Danvers, Massachusetts): an Impella
CP was used in 93.9% of patients, and an Impella 2.5
was used in 3.5% of patients.
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RESEARCH CORRESPONDENCE
Daycase Transcatheter
Aortic Valve Replacement
Preliminary Experience
Transcatheter aortic valve replacement (TAVR) has
evolved from a procedure requiring surgical vascular
access and general anesthesia to one that can be
performed routinely via percutaneous access using
local anesthesia. As a result, the duration of hospital
stay following TAVR has decreased, and next-day
discharge has been shown to be safe for many pa-
tients (1). The primary reason for keeping patients in
the hospital following TAVR is for cardiac
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